Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03353207
Other study ID # HMRF04153036
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 30, 2017
Est. completion date February 8, 2021

Study information

Verified date February 2021
Source Chinese University of Hong Kong
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Background: Previous studies have confirmed that most patients with idiopathic REM sleep behaviour disorder (iRBD) eventually develop neurodegenerative diseases. In addition, REM sleep without atonia (RSWA), a hallmark of RBD feature, is a significant predictor of development of neurodegenerative diseases in patients with iRBD. Some preliminary studies have implied that isolated RSWA in the absence of RBD symptoms may also indicate neurodegeneration. However, this speculation needs to be confirmed by more refined study with sophisticated measures in both RSWA and markers of neurodegeneration Objectives: 1) to determine the differences in striatal dopamine transmission and other markers of neurodegeneration among individuals with isolated RSWA and healthy controls; 2) to examine the correlation of severity of RSWA with striatal dopamine transmission. Design: Case-control study Setting: Community-based sample Participants: 1) iRBD first degree relatives with isolated RSWA (n=18) 2) iRBD first degree relatives without isolated RSWA (n=18) 3) Community-based health controls without isolated RSWA (n=18) Main outcome measures: 1. The dopamine transmission as measured by triple-tracer PET/ CT imaging protocol including 18F-DOPA, 11C-Raclopride and 18F-FDG images; 2. Brain glucose metabolism and neurocognitive measures; 3. Severity of EMG activity during REM sleep


Description:

In the past two decades, a number of studies have confirmed that most patients with idiopathic RBD will eventually develop neurodegenerative diseases, especially α-synucleinopathies. Previous studies, including our preliminary data, suggested that RSWA is a marker of predicting the conversion of neurodegenerative diseases in idiopathic RBD. In other words, RSWA is an early marker of neurodegeneration in patients with idiopathic RBD. However, a number of individuals who are absent of any RBD symptoms (including patients with α-synucleinopathies, also have RSWA, which is described to have isolated RSWA. Only a few studies have attempted to understand the clinical importance and predictive prognosis of isolated RSWA. These preliminary studies suggest that isolated RSWA in healthy subjects may be a silent biomarker of neurodegeneration. However, these preliminary findings need to be replicated and confirmed by more refined study with dopamine neurotransmission neuroimaging. This proposed study will enrich the limited scientific literature of the potential pathogenesis and progression of isolated RSWA. By using an ongoing family study, we have screened a number of individuals with isolated RSWA, who are the first degree relatives of patients with RBD and are presumed to have a higher risk of neurodegeneration. Based on the existing sample, the current study will provide the first neuroimaging data on isolated RSWA to test the hypothesis that isolated RSWA, even in the absence of RBD symptoms, is an early marker of neurodegeneration. Individuals with isolated RSWA are expected to show dopamine dysfunction when compared with individuals without RSWA. If we confirm this hypothesis, the findings in the current study will extend our understanding of the spectrum of RBD and RSWA. The potential implication of our findings is that asymptomatic RSWA, especially in the presence of family history, will harbour the neurodegenerative progression. The results will pave the way for future prospective follow up to determine the course of neurodegeneration. From an etiological understanding, it will help to expand the understanding of the evolution course of synucleinopathy neurodegeneration. From an interventional angle, this study will have significant implication for developing a longer prevention window for neuroprotective trial. The inclusion criteria for the subjects: iRBD first degree relatives with isolated RSWA 1. First degree relatives of patients with iRBD; 2. Age 45 years or above; 3. Absence of dream enactment behaviors; 4. A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the cut-off suggestive of a diagnosis of RBD; 5. Presence of RSWA as measured by v-PSG; RSWA is defined as the percentage of increased EMG activity (phasic or tonic) at least 10% during REM sleep for any channel. 6. for those individuals with moderate to severe obstructive sleep apnea (apnea-hypopnea index, AHI > 15/hour), effective CPAP treatment should be documented and a second night of V-PSG is required to determine RSWA. Community-based health controls without isolated RSWA: 1. No family history of RBD; 2. Age- and sex- matched with isolated RSWA subjects 3. Absence of dream enactment behaviors; 4. A score of RBDQ-HK less than 19; 5. Absence of RSWA as measured by v-PSG; 6. for those individuals with moderate obstructive sleep apnea (AHI > 15/hour), effective CPAP treatment should be documented and a second night of V-PSG is required to determine RSWA.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date February 8, 2021
Est. primary completion date July 1, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 45 Years to 65 Years
Eligibility Inclusion Criteria: 1. No family history of RBD; 2. Age- and sex- matched with isolated RSWA subjects 3. Absence of dream enactment behaviors; 4. A score of RBDQ-HK less than 19; 5. Absence of RSWA as measured by v-PSG; 6. for those individuals with moderate obstructive sleep apnea (AHI > 15/hour), effective CPAP treatment should be documented and a second night of V-PSG is required to determine RSWA. Exclusion Criteria: 1. Presence of dream enactment behaviors by self-report or documented by v-PSG; 2. Presence of narcolepsy and other neurological diseases that may give rise to RBD and RWSA; 3. Presence of neurodegenerative diseases; 4. A total score of the MOCA = 22 and the CDR = 1. 5. On medication that potentially increases EMG activity and triggers the symptoms of RBD, such as antidepressants; 6. On medication that affects dopamine neural transmission; 7. Not capable of giving informed consent for participation of the study.

Study Design


Locations

Country Name City State
Hong Kong Shatin Hospital Shatin

Sponsors (1)

Lead Sponsor Collaborator
Chinese University of Hong Kong

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dopamine neurotransmission PET dopamine neurotransmission with a specific interest in striatal dopamine transmission 24 months
Secondary REMREEA Correlations of severity of REMREEA with dopamine transmission, brain glucose metabolism, and neurocognitive measures. 24 months
See also
  Status Clinical Trial Phase
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Completed NCT05788133 - The Role of Humanoid Robot in Neuropsychological Assessment and Cognitive Training. N/A
Completed NCT05080777 - Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems N/A
Completed NCT03295786 - Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease Phase 1/Phase 2
Recruiting NCT04265482 - Community-based Cohort of Functional Decline in Subjective Cognitive Complaint Elderly
Not yet recruiting NCT02222779 - Quantification of Transition Metals N/A
Recruiting NCT01291550 - Electronic Nose for Diagnosis of Neurodegenerative Diseases Via Breath Samples N/A
Completed NCT01450891 - Health Technology Assessment of Diagnostic Approaches in Alzheimer's Disease N/A
Completed NCT01953523 - Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions N/A
Recruiting NCT06148233 - CSF1R PET Probe [18F]CSF-23 in Alzheimer's Disease Brain Imaging N/A
Completed NCT03538522 - A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831 Phase 2
Completed NCT06251830 - Increasing Diagnosis Rates While Reducing Examination Time: Can MR Fingerprinting Deliver on Its Promise?
Recruiting NCT04472130 - Neurodegenerative Diseases Registry
Completed NCT05095870 - Evaluation of the Peripheral Nerve Ultrasound as a Diagnostic Tool in CANVAS Neuropathies
Recruiting NCT05784090 - Correlation Between Melatonin Levels in Different Biological Fluids
Completed NCT02108769 - Yogic Breathing Changes Salivary Components N/A
Recruiting NCT05508789 - A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5) Phase 3
Recruiting NCT05235802 - Long-term Follow-up in Severe Traumatic Brain Injury
Recruiting NCT04820881 - Cerebrovascular Reactivity and Oxygen Metabolism as Markers of Neurodegeneration After Traumatic Brain Injury
Completed NCT06180213 - Study of Cerebral Glucose Metabolism in Neurodegenerative Diseases and Head Trauma